Potential for molecularly targeted therapy against epidermal growth factor receptor ligands

Shingo Miyamoto, Tatsuya Fukami, hiroshi yagi, Masahide Kuroki, Fusanori Yotsumoto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Monoclonal antibodies and tyrosine kinase inhibitors against ErbB receptors have been developed and have progressed to clinical applications following several decades of research in cancer cell biology. Inhibition of epidermal growth factor receptor (EGFR) signaling represents a particularly promising arena for the application of molecularly targeted cancer therapies. In EGFR signaling inhibition, EGFR itself has been recognized as a target in epithelial malignancies, though clinical studies using EGFR antagonists have not always resulted in favorable clinical outcomes. The aberrant enhancement of EGFR ligand expression is speculated to be one of several different molecular mechanisms accounting for the acquired resistance to EGFR antagonists. Recently, emerging evidence has indicated that EGFR ligands deserve considerable attention as potential targets for cancer therapy. In this review, we discuss the EGFR signaling inhibition strategies directed at EGFR ligands such as HB-EGF and amphiregulin.

Original languageEnglish
Pages (from-to)823-830
Number of pages8
JournalAnticancer Research
Volume29
Issue number3
Publication statusPublished - Mar 2009

Fingerprint

Epidermal Growth Factor Receptor
Ligands
Therapeutics
Neoplasms
Protein-Tyrosine Kinases
Cell Biology
Monoclonal Antibodies
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Miyamoto, S., Fukami, T., yagi, H., Kuroki, M., & Yotsumoto, F. (2009). Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Research, 29(3), 823-830.

Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. / Miyamoto, Shingo; Fukami, Tatsuya; yagi, hiroshi; Kuroki, Masahide; Yotsumoto, Fusanori.

In: Anticancer Research, Vol. 29, No. 3, 03.2009, p. 823-830.

Research output: Contribution to journalArticle

Miyamoto, S, Fukami, T, yagi, H, Kuroki, M & Yotsumoto, F 2009, 'Potential for molecularly targeted therapy against epidermal growth factor receptor ligands', Anticancer Research, vol. 29, no. 3, pp. 823-830.
Miyamoto, Shingo ; Fukami, Tatsuya ; yagi, hiroshi ; Kuroki, Masahide ; Yotsumoto, Fusanori. / Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. In: Anticancer Research. 2009 ; Vol. 29, No. 3. pp. 823-830.
@article{ef90f82afc174e84beee9ad7649a7077,
title = "Potential for molecularly targeted therapy against epidermal growth factor receptor ligands",
abstract = "Monoclonal antibodies and tyrosine kinase inhibitors against ErbB receptors have been developed and have progressed to clinical applications following several decades of research in cancer cell biology. Inhibition of epidermal growth factor receptor (EGFR) signaling represents a particularly promising arena for the application of molecularly targeted cancer therapies. In EGFR signaling inhibition, EGFR itself has been recognized as a target in epithelial malignancies, though clinical studies using EGFR antagonists have not always resulted in favorable clinical outcomes. The aberrant enhancement of EGFR ligand expression is speculated to be one of several different molecular mechanisms accounting for the acquired resistance to EGFR antagonists. Recently, emerging evidence has indicated that EGFR ligands deserve considerable attention as potential targets for cancer therapy. In this review, we discuss the EGFR signaling inhibition strategies directed at EGFR ligands such as HB-EGF and amphiregulin.",
author = "Shingo Miyamoto and Tatsuya Fukami and hiroshi yagi and Masahide Kuroki and Fusanori Yotsumoto",
year = "2009",
month = "3",
language = "English",
volume = "29",
pages = "823--830",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Potential for molecularly targeted therapy against epidermal growth factor receptor ligands

AU - Miyamoto, Shingo

AU - Fukami, Tatsuya

AU - yagi, hiroshi

AU - Kuroki, Masahide

AU - Yotsumoto, Fusanori

PY - 2009/3

Y1 - 2009/3

N2 - Monoclonal antibodies and tyrosine kinase inhibitors against ErbB receptors have been developed and have progressed to clinical applications following several decades of research in cancer cell biology. Inhibition of epidermal growth factor receptor (EGFR) signaling represents a particularly promising arena for the application of molecularly targeted cancer therapies. In EGFR signaling inhibition, EGFR itself has been recognized as a target in epithelial malignancies, though clinical studies using EGFR antagonists have not always resulted in favorable clinical outcomes. The aberrant enhancement of EGFR ligand expression is speculated to be one of several different molecular mechanisms accounting for the acquired resistance to EGFR antagonists. Recently, emerging evidence has indicated that EGFR ligands deserve considerable attention as potential targets for cancer therapy. In this review, we discuss the EGFR signaling inhibition strategies directed at EGFR ligands such as HB-EGF and amphiregulin.

AB - Monoclonal antibodies and tyrosine kinase inhibitors against ErbB receptors have been developed and have progressed to clinical applications following several decades of research in cancer cell biology. Inhibition of epidermal growth factor receptor (EGFR) signaling represents a particularly promising arena for the application of molecularly targeted cancer therapies. In EGFR signaling inhibition, EGFR itself has been recognized as a target in epithelial malignancies, though clinical studies using EGFR antagonists have not always resulted in favorable clinical outcomes. The aberrant enhancement of EGFR ligand expression is speculated to be one of several different molecular mechanisms accounting for the acquired resistance to EGFR antagonists. Recently, emerging evidence has indicated that EGFR ligands deserve considerable attention as potential targets for cancer therapy. In this review, we discuss the EGFR signaling inhibition strategies directed at EGFR ligands such as HB-EGF and amphiregulin.

UR - http://www.scopus.com/inward/record.url?scp=64949119273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949119273&partnerID=8YFLogxK

M3 - Article

C2 - 19414315

AN - SCOPUS:64949119273

VL - 29

SP - 823

EP - 830

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -